RAPT Therapeutics Inc (RAPT) gains 1.88% for July 21

Equities Staff  |

RAPT Therapeutics Inc (NASDAQ: RAPT) shares gained 1.88%, or $0.63 per share, to close Wednesday at $34.15. After opening the day at $33.16, shares of RAPT fluctuated between $34.19 and $32.20. 133,258 shares traded hands a decrease from their 30 day average of 352,470. Wednesday's activity brought RAPT’s market cap to $854,057,589.

RAPT is headquartered in South San Francisco, California..

About RAPT Therapeutics Inc

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

Visit RAPT Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on RAPT Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: RAPT Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content